Phase I study of LDK378 in pediatric malignancies with a genetic alteration in ALK Estimate the MTD and/or RDE of LDK378 as a single agent when administered orally to pediatric patients with ALK-activated tumors in the fasted and fed state

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Exploratory evaluation of surrogate markers of cardiovascular risk in patients with active chronic plaque-type psoriasis To evaluate flow mediated dilation (FMD) by Doppler ultrasound at week 12 in subjects in treatment arm A (300 mg Secukinumab) compared to the pooled group of patients in treatment arms C and D (placeb...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy of Rasilez® (Aliskiren) compared to ramipril in the treatment of moderate systolic hypertensive patients Comparer l'efficacité d'aliskiren 150/300 mg à celle de ramipril 5/10 mg sur la réduction de la PASma à l’état final (V4 soit après 8 semaines de traitement en double-aveugle) par rapport à l'état bas...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Pharmacokinetics, pharmacodynamics and safety of DEB025/alisporivir in combination with ribavirin therapy in chronic hepatitis C genotype 2 and 3 patients who have previously failed interferon therapy or are intolerant or unable to take interferon To evaluate pharmacodynamics, pharmacokinetic between 2 treatment groups receiving different doses of DEB025 in combination with RBV

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A phase III multi-center, open-label, randomized study of the efficacy of nilotinib versus imatinib in adult patients with Philadelphia chromosome positive (Ph+ ) chronic myelogenous leukemia in chronic phase (CML - CP) who have suboptimal cytogenetic response (CyR) on imatinib To evaluate the complete cytogenetic response (CCyR ) rate at 12 months of nilotinib compared to imatinib in adult patients with Ph+ CML in CP who have a suboptimal cytogenetic response to imatinib.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Efficacy and safety study of QAW039 in the treatment of patients with moderate to severe atopic dermatitis The purpose of this study is to determine whether QAW039 is safe and has beneficial effects in people who have moderate to severe atopic dermatitis (AD) - Eczema Area and Severity Index (EASI) sco...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A multicenter, double-blind, randomized study to compare the efficacy of 24 weeks treatment with fixed combination therapy of vildagliptin and metformin (25/1000 mg bid) versus metformin monotherapy (1000 mg bid) in patients with type 2 diabetes inadequately controlled with metformin monotherapy To demonstrate that the HbA1c reduction with fixed dose combination therapy of vildagliptin and metformin (25/1000 mg bid) is superior to that with metformin monotherapy (1000 mg bid) after 24 weeks o...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A study to check how safe, beneficial and tolerable the drug canakinumab, along with childhood vaccines, is for patients with crypoyrin associated periodic syndromes (CAPS) To assess the long-term efficacy of canakinumab with respect to the maintenance of treatment response in CAPS patients who completed the CACZ885D2307 study

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Study in patients with moderate to severe psoriasis with secukinumab To demonstrate that secukinumab has superior efficacy compared to placebo on the pruritus intensity VAS (the worst itching within a recall period of 24 hours as part of the Patients Global Assessment ...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Evaluation of drug-drug interaction between LCZ696 and sildenafil in subjects with mild to moderate hypertension - To investigate the effect of LCZ696 on single dose pharmacokinetics of sildenafil in subjects with mild to moderate hypertension. - To investigate the effect of sildenafil on the steady-state pharm...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune